AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Atara Biotherapeutics Maintains $16 Price Target After Mizuho Securities Reaffirms Buy Rating
ByAinvest
Monday, Aug 18, 2025 10:47 pm ET1min read
Mizuho Securities reaffirms their Buy rating on Atara Biotherapeutics (ATRA) with a price target of $16.00. The analyst consensus is a Moderate Buy with an average price target of $15.00. The company reported Q2 revenue of $17.58 million and a net profit of $2.39 million, compared to $28.64 million in revenue and a $19.05 million GAAP net loss last year. Corporate insider sentiment is neutral on the stock.
Mizuho Securities has reaffirmed its Buy rating on Atara Biotherapeutics (ATRA) with a price target of $16.00. The analyst consensus is a Moderate Buy, with an average price target of $15.00 [1]. The company reported Q2 revenue of $17.58 million and a net profit of $2.39 million, compared to $28.64 million in revenue and a $19.05 million GAAP net loss last year. Corporate insider sentiment on the stock is neutral [1].References:
[1] https://www.investing.com/news/analyst-ratings/3
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet